Covid-19 Vaccines Return Trillions, Study Finds
Reanalysis estimates first-year global returns of $6.43 trillion to $64.3 trillion on $79.4 billion invested in vaccine development.
Updated on Nov. 5, 2026 in COVID-19
Live Poll
Do you think government spending on public health protects the economy too?
Researchers reanalyzed the economic value of covid-19 vaccines and estimated global returns of $6.43 trillion to $64.3 trillion in the first year after rollout. The new range replaces an earlier preprint estimate of $4.8 trillion to $37.9 trillion that was revised during peer review.
Why it matters
The estimates put a dollar value on the benefits of rapid pandemic vaccine development, a question policymakers weigh when funding future preparedness. The wide gap between the two methods shows how much the result depends on the economic framework chosen.
The analysis draws on data from 173 countries and models 14 million to 20 million deaths prevented in the first year, with returns of $59.70 to $809 per $1 spent. The wide spread reflects the choice of cost-effectiveness versus cost-benefit method, and how the value of a life is counted remains open to debate.
The details
The researchers switched from the Value of Statistical Life Years to the Value of Statistical Life during peer review, which substantially raised the cost-benefit figure. Vaccine benefits were highest in richer countries, while poorer countries received doses later and so saved fewer lives.
Timeline
First 12 months after covid-19 vaccine rollout: benefits measured across 173 countries.
Next 10 years: researchers project a significant probability of another pandemic.
Big Picture
The new range revises the earlier preprint estimate of $4.8 trillion to $37.9 trillion, which was published before peer review changed the valuation method. Economic studies of pandemic vaccines increasingly show that the reported return depends heavily on whether lives are valued by quality-adjusted years or by statistical life value.
The findings bear on how governments justify spending on vaccine development and stockpiles for future outbreaks. For individuals, the study suggests that vaccine access timing shaped who benefited most in the first year.
The takeaway
Economic valuations of pandemic vaccines can differ by orders of magnitude depending on method, so readers should look at both the assumptions and the cross-country distribution of benefits. Access timing mattered as much as the vaccines themselves.
Further reading
Explore more COVID-19 coverage for context on how vaccine policy and outcomes have been tracked.
Source note: This article includes information reported by New Scientist.
Live Poll
Do you think government spending on public health protects the economy too?
